Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Net Income: 2015-2025

Historic Net Income for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to -$19.5 million.

  • Cartesian Therapeutics' Net Income fell 30.10% to -$19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.7 million, marking a year-over-year increase of 59.92%. This contributed to the annual value of -$77.4 million for FY2024, which is 64.76% up from last year.
  • Cartesian Therapeutics' Net Income amounted to -$19.5 million in Q3 2025, which was up 2.72% from -$20.1 million recorded in Q2 2025.
  • Over the past 5 years, Cartesian Therapeutics' Net Income peaked at $15.0 million during Q2 2024, and registered a low of -$196.7 million during Q4 2023.
  • In the last 3 years, Cartesian Therapeutics' Net Income had a median value of -$18.0 million in 2023 and averaged -$30.7 million.
  • Per our database at Business Quant, Cartesian Therapeutics' Net Income surged by 5,505.67% in 2022 and then slumped by 3,437.15% in 2023.
  • Quarterly analysis of 5 years shows Cartesian Therapeutics' Net Income stood at $12.2 million in 2021, then tumbled by 51.85% to $5.9 million in 2022, then crashed by 3,437.15% to -$196.7 million in 2023, then skyrocketed by 87.66% to -$24.3 million in 2024, then slumped by 30.10% to -$19.5 million in 2025.
  • Its Net Income was -$19.5 million in Q3 2025, compared to -$20.1 million in Q2 2025 and -$19.9 million in Q1 2025.